Trade

with

Synergy Pharmaceuticals Inc
(NASDAQ: SGYP)
AdChoices
2.81
+0.03
+1.08%
After Hours :
2.81
0.00
0.00%

Open

2.78

Previous Close

2.78

Volume (Avg)

433.66k (811.89k)

Day's Range

2.75-2.82

52Wk Range

2.45-6.70

Market Cap.

266.37M

Dividend Rate ( Yield )

-

Beta

0.67

Shares Outstanding

94.80M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -62.12M

    • Market Cap.

    • 266.37M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.67

    • Forward P/E

    • -3.14

    • Price/Sales

    • -

    • Price/Book Value

    • 6.96

    • Price/Cash flow

    • -4.11

      • EBITDA

      • -62.05M

      • Return on Capital %

      • -99.40

      • Return on Equity %

      • -121.29

      • Return on Assets %

      • -99.40

      • Book Value/Share

      • 0.40

      • Shares Outstanding

      • 94.80M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 13.17

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.60

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 3.12

              • 1.52

              • Quick Ratio

              • 2.85

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.48

              • 1.91

              • Book Value/Share

              • 0.40

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -3.46

                • 65.79

                • P/E Ratio 5-Year High

                • -26.32

                • 237.47

                • P/E Ratio 5-Year Low

                • -2.51

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.69

                • Price/Book Value

                • 7.06

                • 3.46

                • Price/Cash Flow Ratio

                • -4.11

                • 22.12

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -121.29

                        (-409.40)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -99.40

                        (-157.60)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -121.29

                        (-409.30)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • -

                      • 1.80

                      • Asset Turnover

                      • -

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -62.31M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -4.11
                      Ownership

                      Institutional Ownership

                      30.33%

                      Top 10 Institutions

                      22.45%

                      Mutual Fund Ownership

                      18.94%

                      Float

                      98.27%

                      5% / Insider Ownership

                      0.69%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • SPDR® S&P Biotech ETF

                      •  

                        2,274,615

                      • -1.92

                      • 2.40

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        2,228,472

                      • 0.00

                      • 2.35

                      • Vanguard Small Cap Index

                      •  

                        1,491,348

                      • 1.48

                      • 1.57

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,414,007

                      • 0.00

                      • 1.49

                      • iShares Russell 2000 (AU)

                      •  

                        1,410,454

                      • -1.46

                      • 1.49

                      • iShares Nasdaq Biotechnology

                      •  

                        1,226,325

                      • -0.47

                      • 1.29

                      • Vanguard Small Cap Value Index Fund

                      •  

                        794,948

                      • 2.10

                      • 0.84

                      • Vanguard Extended Market Index Fund

                      •  

                        781,117

                      • 8.40

                      • 0.82

                      • iShares Russell 2000 Growth

                      •  

                        664,167

                      • 0.34

                      • 0.70

                      • UBS (Lux) EF Biotech (USD)

                      •  

                        588,300

                      • 0.00

                      • 0.63

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • State Street Corp

                      •  

                        4,963,086

                      • +46.50%

                      • 5.27

                      • Vanguard Group, Inc.

                      •  

                        4,766,278

                      • +5.47%

                      • 5.06

                      • BlackRock Fund Advisors

                      •  

                        3,418,498

                      • +1.47%

                      • 3.63

                      • Fidelity Management and Research Company

                      •  

                        2,470,956

                      • -6.88%

                      • 2.63

                      • Baker Bros Advisors LLC

                      •  

                        1,758,271

                      • 0.00%

                      • 1.87

                      • Wall Street Associates Llc

                      •  

                        948,500

                      • -0.16%

                      • 1.01

                      • Northern Trust Investments, N.A.

                      •  

                        931,510

                      • -9.03%

                      • 0.99

                      • Morgan Stanley Smith Barney LLC

                      •  

                        764,031

                      • -0.11%

                      • 0.81

                      • UBS Global Asset Management Zurich

                      •  

                        619,800

                      • 0.00%

                      • 0.66

                      • Geode Capital Management, LLC

                      •  

                        488,121

                      • +10.68%

                      • 0.52

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      Small Growth

                      Synergy Pharmaceuticals, Inc., was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gast...morerointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C i...mores characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company’s main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.lessless

                      Key People

                      Gary S. Jacob

                      CEO/Chairman of the Board/Director/President

                      Bernard F. Denoyer

                      CFO/Chief Accounting Officer/Secretary/Senior VP, Divisional

                      Dr. Kunwar Shailubhai,PhD

                      Chief Scientific Officer/Executive VP

                      Alan F. Joslyn,PhD

                      Director

                      Dr. Christopher McGuigan,PhD

                      Director

                      • Synergy Pharmaceuticals Inc

                      • 420 Lexington Avenue

                      • New York, NY 10170

                      • USA.Map

                      • Phone: +1 212 297-0020

                      • Fax: +1 212 297-0019

                      • synergybio.net

                      Incorporated

                      2005

                      Employees

                      25

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: